ArticleJournal of experimental pharmacology2022
Antidiabetic Activity of Hydromethanolic Extract of Crude
Article in Journal of experimental pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- The Nutraceutical Potential of Blackcurrant (Nutrients · 2026Review
- Evaluation of the anti-hyperglycemic and anti-dyslipidemic potential of the hydroethanolic extract ofMetabolism open · 2026Article
- Phytochemical composition, in vitro antioxidant and antibacterial activities of Dorstenia barnimiana Schweinf leaf extracts.BMC complementary medicine and therapies · 2026Article
- Royal jelly ameliorates behavioral deficit and hippocampal damage induced by inhalation exposure to xylene.Scientific reports · 2025Article
- Medicinal plants administered to control hypertension in Ethiopia: ethnomedicine, pharmacology, nutraceutical, phytochemistry, toxicology, and policy perspectives.Frontiers in cardiovascular medicine · 2025Review
- Article
- Validation of Antidiabetic and Antihyperlipidemic Effects of 80% Methanolic Extract of theEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Luteolin-Rich Extract ofOxidative medicine and cellular longevity · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite modern therapeutic armamentaria, DM remains a 21st-century public health menace. Novel phytomedicines are a rapidly expanding focus of research. The juice of
methodsIn this experimental study, simple random sampling was applied. Healthy male mice were used in normoglycemic and oral glucose-tolerance test (OGTT) models. Streptozotocin (IP, 150 mg/kg)-administered diabetic male mice were utilized. Animals were randomly divided into five groups of six each. Group I received 10 mL/kg distilled water, groups II-IV received 100 (DB100), 200 (DB200), and 400 (DB400) mg/kg crude extract, respectively, and group V received glibenclamide 5 mg/kg. A sham group (group VI) was added that received 10 mL/kg distilled water. All treatments were given orally. FBG, serum-lipid profiles, and body-weight changes were then measured. In vitro α-amylase inhibitory activity was also evaluated.
resultsThe doses were atoxic up to 2,000 mg/kg. There was α-amylase inhibition activity of 67.52% at 500 μg/mL with an IC
conclusionThe present study confirmed the safety and promising in vivo antidiabetic and antidyslipidemic activity of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.